PyroGenesis Canada Inc.

Condensed Consolidated Interim Financial Statements Three months ended March 31, 2022 (Unaudited)

The accompanying unaudited condensed consolidated financial statements of PyroGenesis Canada Inc. have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these unaudited condensed consolidated interim financial statements for the period ended March 31, 2022.

PyroGenesis Canada Inc. Condensed Consolidated Interim Statements of Financial Position

(Unaudited)

Assets Current assets Cash and cash equivalents Accounts receivable Costs and profits in excess of billings on uncompleted contracts Inventory Investment tax credits receivable Income taxes receivable Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets Non-current assets	6 7 8 17 9 11	\$ 6,612,624 17,177,027 5,863,935 1,273,161 210,628 37,305 2,402,331 320,279 334,660 2,897,821 37,129,770	\$ 12,202,513 17,639,616 4,922,710 887,590 256,513 117,029 1,328,452 311,111 375,789 717,661 38,758,984
Current assets Cash and cash equivalents Accounts receivable Costs and profits in excess of billings on uncompleted contracts Inventory Investment tax credits receivable Income taxes receivable Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets	7 8 17 9 11	17,177,027 5,863,935 1,273,161 210,628 37,305 2,402,331 320,279 334,660 2,897,821 37,129,770	17,639,616 4,922,710 887,590 256,513 117,029 1,328,452 311,111 375,789 717,661
Cash and cash equivalents Accounts receivable Costs and profits in excess of billings on uncompleted contracts Inventory Investment tax credits receivable Income taxes receivable Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets	7 8 17 9 11	17,177,027 5,863,935 1,273,161 210,628 37,305 2,402,331 320,279 334,660 2,897,821 37,129,770	17,639,616 4,922,710 887,590 256,513 117,029 1,328,452 311,111 375,789 717,661
Accounts receivable Costs and profits in excess of billings on uncompleted contracts Inventory Investment tax credits receivable Income taxes receivable Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets	7 8 17 9 11	17,177,027 5,863,935 1,273,161 210,628 37,305 2,402,331 320,279 334,660 2,897,821 37,129,770	17,639,616 4,922,710 887,590 256,513 117,029 1,328,452 311,111 375,789 717,661
Costs and profits in excess of billings on uncompleted contracts Inventory Investment tax credits receivable Income taxes receivable Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets	8 17 9 11	5,863,935 1,273,161 210,628 37,305 2,402,331 320,279 334,660 2,897,821 37,129,770	4,922,710 887,590 256,513 117,029 1,328,452 311,111 375,789 717,661
Inventory Investment tax credits receivable Income taxes receivable Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets	17 9 11	1,273,161 210,628 37,305 2,402,331 320,279 334,660 2,897,821 37,129,770	887,590 256,513 117,029 1,328,452 311,111 375,789 717,661
Investment tax credits receivable Income taxes receivable Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets	9 11	210,628 37,305 2,402,331 320,279 334,660 2,897,821 37,129,770	256,513 117,029 1,328,452 311,111 375,789 717,661
Income taxes receivable Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets	11	37,305 2,402,331 320,279 334,660 2,897,821 37,129,770	117,029 1,328,452 311,111 375,789 717,661
Current portion of deposits Current portion of royalties receivable Contract assets Prepaid expenses Total current assets		2,402,331 320,279 334,660 2,897,821 37,129,770	1,328,452 311,111 375,789 717,661
Current portion of royalties receivable Contract assets Prepaid expenses Total current assets		320,279 334,660 2,897,821 37,129,770	311,111 375,789 717,661
Contract assets Prepaid expenses Total current assets	11	334,660 2,897,821 37,129,770	375,789 717,661
Prepaid expenses Total current assets	11	2,897,821 37,129,770	717,661
Total current assets	11	37,129,770	
	11		38,758,984
Non-current assets	11		
	11		
Deposits		236,297	248,756
Strategic investments	10	14,681,413	14,901,659
Property and equipment		3,619,631	3,712,937
Right-of-use assets		5,599,769	5,765,993
Royalties receivable		939,739	947,543
Intangible assets		2,580,127	2,774,198
Goodwill		2,660,607	2,660,607
Total assets		67,447,353	69,770,677
Liabilities			
Current liabilities			
Bank indebtedness		943,475	_
Accounts payable and accrued liabilities	12	9,378,832	10,069,177
Billings in excess of costs and profits on uncompleted contracts	13	9,076,618	9,400,231
Current portion of term loans	14	83,233	83,004
Current portion of lease liabilities	14	2,937,013	2,934,236
Balance due on business combination		2,292,262	2,242,503
Income taxes payable		71,963	23,048
Total current liabilities		24,783,396	24,752,199
Non-current liabilities			
Lease liabilities		2,339,792	2,389,729
Term loans	14	211,986	107,901
Balance due on business combination		1,742,914	1,709,700
Deferred income taxes		-	42,394
Total liabilities		29,078,088	29,001,923
Shareholders' equity	15		
Common shares and warrants	10	82,104,086	82,104,086
Contributed surplus		21,548,685	19,879,055
Accumulated other comprehensive income		41,100	3,444
Deficit		(65,324,606)	(61,217,831)
Total shareholders' equity		38,369,265	40,768,754
Total liabilities and shareholders' equity		67,447,353	69,770,677

Contingent liabilities [notes 22].

PyroGenesis Canada Inc.

Condensed Consolidated Interim Statements of Comprehensive Income (Loss) (Unaudited)

Notes		2021
NOLES	\$	2021 \$
5	4,206,762	6,264,503
17	3,155,039	4,121,493
	1,051,723	2,143,010
17	5,612,368	3,725,435
	482,432	286,307
	6,094,800	4,011,742
	(5,043,077)	(1,868,732)
10	1,176,755	5,634,722
18	(183,900)	(53,087)
	(4,050,222)	3,712,903
	56,553	_
	(4,106,775)	3,712,903
s		
	37,656	-
	(4,069,119)	3,712,903
		0.00
		0.02
	17 17 17 10	\$ 5 4,206,762 17 3,155,039 1,051,723 17 5,612,368 482,432 6,094,800 (5,043,077) 10 1,176,755 18 (183,900) (4,050,222) 56,553 (4,106,775) Ss foreign 37,656

The accompanying notes form an integral part of the condensed consolidated interim financial statements.

PyroGenesis Canada Inc. Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)

	Notes	Number of common s shares	Common shares and warrants	Contributed Surplus	Accumulated other comprehensive income	Deficit	Total
Balance - December 31, 2021 Share-based payments Other comprehensive income for the year Net loss and comprehensive loss	15	170,125,795 _ _ _	\$	\$ 19,879,055 1,669,630 – –		<u>(61,217,831)</u> (61,217,831) (4,106,775)	\$ 40,768,754 1,669,630 37,655 (4,106,775)
Balance – March 31, 2022		170,125,795	82,104,086	21,548,685	41,099	(65,324,606)	38,369,265
Balance - December 31, 2020 Shares issued upon exercise of stock options	s 15	159,145,993 11,000	67,950,069 10,315	10,480,310 (3,935)	- -	(19,007,273) _	59,423,106 6,380
Shares issued upon exercise of warrants and compensation options Share-based payments Net earnings and comprehensive income	15 15	5,344,549 _ _	8,057,581 _ _	_ 922,340 _	- -	- - 3,712,903	8,057,581 922,340 3,712,903
Balance – March 31, 2021		164,501,542	76,017,965	11,398,715	_	(15,294,370)	72,122,310

The accompanying notes form an integral part of the condensed consolidated interim financial statements.

PyroGenesis Canada Inc. Condensed Consolidated Interim Statements of Cash Flows

(Unaudited)

	Notes	Three months end 2022	
			<u>2021</u> \$
Cash flows provided by (used in)		Ť	Ψ
Operating activities			
Net earnings (loss)		(4,106,775)	3,712,903
Adjustments for:			-, ,
Share-based payments		1,669,630	922,340
Depreciation of property and equipment		141,095	76,317
Depreciation of right-of-use assets		166,224	101,794
Amortization and write-off of intangible assets		218,759	6,780
Amortization of contract assets		41,129	134,863
Finance costs		183,900	53,087
Change in fair value of investments		(1,176,755)	(5,634,722)
Income taxes		86,245	-
Unrealized foreign exchange		34,390	-
		(2,742,158)	(626,638)
Net change in balances related to operations	16	(5,023,565)	(6,008,484)
		(7,765,723)	(6,635,122)
Investing activities		(1,100,120)	(0,000,122)
Additions to property and equipment		(126,172)	(549,576)
Additions to intangible assets		3,407	(75,668)
Purchase of strategic investments		-	(3,392,184)
Disposal of strategic investments	10	1,397,001	10,866,302
·		1,274,236	6,848,874
Financing activities			, ,
Increase in bank indebtedness		943,475	-
Interest paid		(97,510)	(50,209)
Repayment of term loans		(8,166)	(2,973)
Repayment of lease liabilities		(47,160)	(55,086)
Proceeds from issuance of other term loans		107,700	-
Proceeds from issuance of shares upon exercise of warrants		-	8,057,581
Proceeds from issuance of shares upon exercise of stock option	าร	-	6,380
		898,339	7,955,693
Effect of exchange rate changes on cash denominated in foreig	n currenc	cies 3,259	_
Net increase (decrease) in cash and cash equivalents		(5,589,889)	8,169,445
Cash and cash equivalents - beginning of period		12,202,513	18,104,899
Cash and cash equivalents - end of period		6,612,624	26,274,344
Supplemental cash flow disclosure			
Non-cash transactions:			
Purchase of intangible assets included in accounts payable		4,038	53,576
Purchase of property and equipment included in accounts paya	ble	83,697	177,193
Accretion of balance purchase price payable		82,973	_ , ==
Accretion interest on royalties receivable		1,364	_
Accretion on term loan		4,781	_
The accompanying notes form an integral part of the condensed consolidated	interim fina	ancial statements	

The accompanying notes form an integral part of the condensed consolidated interim financial statements

PyroGenesis Canada Inc. Notes to the Condensed Consolidated Interim Financial Statements

For the periods ended March 31, 2022 and 2021 (Unaudited)

1. Nature of operations

PyroGenesis Canada Inc. and its subsidiaries (collectively, the "Company"), incorporated under the laws of the Canada Business Corporations Act, was formed on July 11, 2011. The Company owns patents of advanced waste treatment systems technology and designs, develops, manufactures and commercialises advanced plasma processes and sustainable solutions to reduce greenhouse gases. The Company is domiciled at 1744 William Street, Suite 200, Montreal, Quebec. The Company is publicly traded on the TSX Exchange under the Symbol "PYR" on NASDAQ in the USA under the symbol "PYR" and on the Frankfurt Stock Exchange (FSX) under the symbol "8PY ".

2. Basis of preparation

(a) Statement of compliance

These financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB").

These condensed consolidated interim financial statements do not include all of the necessary information required for full annual financial statements in accordance with IFRS and should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2020.

These financial statements were approved and authorized for issuance by the Board of Directors on May 16, 2022.

(b) Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency.

(c) Basis of measurement

These financial statements have been prepared on the historical cost basis except for:

- (i) strategic investments which are accounted for at fair value,
- (ii) stock-based payment arrangements, which are measured at fair value on the grant date pursuant to IFRS 2, Share-based Payment; and
- (iii) lease liabilities, which are initially measured at the present value of minimum lease payments

(d) Basis of consolidation

For financial reporting purposes, subsidiaries are defined as entities controlled by the Company. The Company controls an entity when it has power over the investee; it is exposed to, or has rights to, variable returns from its involvement with the entity; and it has the ability to affect those returns through its power over the entity.

In instances where the Company does not hold a majority of the voting rights, further analysis is performed to determine whether or not the Company has control of the entity. The Company is deemed to have control when, according to the terms of the shareholder's and/or other agreements, it makes most of the decisions affecting relevant activities.

These consolidated financial statements include the accounts of the Company and its subsidiaries, Drosrite International LLC and Pyro Green-Gas Inc. and its subsidiaries. Drosrite International LLC is owned by a member of the Company's key management personnel and close member of the Chief Executive Officer ("CEO") and controlling shareholder's family and is deemed to be controlled by the Company. Pyro Green-Gas (formerly AirScience Technologies Inc. until the renaming on September 14, 2021) was acquired by the Company on August 11, 2021 (see note 5). All transactions and balances between the Company and its subsidiaries have been eliminated upon consolidation.

The accounting policies set out below have been applied consistently in the preparation of the financial statements of all years presented. Finance costs and changes in fair value of strategic investments are excluded from the loss from operations in the consolidated statement of comprehensive income (loss).

PyroGenesis Canada Inc. Notes to the Condensed Consolidated Interim Financial Statements For the periods ended March 31, 2022 and 2021

(Unaudited)

3. Significant accounting judgments, estimates and assumptions

The significant judgments, estimates and assumptions applied by the Company's in these condensed consolidated interim financial statements are the same as those applied by the Company in its audited annual financial statements as at and for the year ended December 31, 2021.

4. Business combination in fiscal 2021

On August 11, 2021, the Company completed the acquisition of Pyro Green-Gas Inc. and its subsidiaries (formerly AirScience Technologies Inc. prior to its renaming on September 14, 2021), a Montreal-based company which offers technologies, equipment, and expertise in the area of biogas upgrading, as well as air pollution controls, for a maximum purchase price consideration of \$4.4 million in cash, subject to customary post-closing adjustments. In addition, the Company settled a pre-existing loan receivable from Pyro Green-Gas Inc. of approximately \$1.7 million. The transaction was executed essentially through a purchase of the entirety of the common class "A" shares of Pyro Green-Gas Inc. This acquisition enables the Company to springboard into the renewable natural gas market and provides an advantage compared to building its own operations. In addition, the Company will now have a presence in Italy and India, and the acquisition will provide potential synergies with the Company's land-based waste destruction offerings. The purchase price will be paid upon the achievement of various contract and business-related milestones by Pyro Green-Gas Inc. The Company's assessment is that these milestones will be realized at various moments during the next 30 months. The contingent consideration was estimated using a discount rate of 8%.

The acquisition was accounted for using the purchase method and the final allocation of the purchase price is as follows:

	\$
Total consideration	
Consideration paid at closing	1
Contingent consideration	3,841,999
Consideration paid at closing and continent consideration	3,842,000
Settlement of pre-existing loan receivable from Pyro Green-Gas	1,744,400
	5,586,400
	December 31, 2021
	Final
	\$
Net assets acquired	
Current assets ¹	5,186,086
ROU asset	477,608
Property and equipment	42,552
Intangible assets and Goodwill ²	4,780,607
Deferred income tax asset	79,360
Current liabilities	(4,507,907)
Non-current liabilities	(471,906)
	5,586,400

¹ Includes \$807,946 of cash and trade receivables with a net fair value of \$3.3 million, including an allowance for doubtful accounts of \$0.5 million.

² The goodwill of \$2.7 million recorded on the transaction is mainly attributable to the expected growth in biogas upgrading market and the

expertise of the workforce, and it is not expected to be deductible for tax purposes.

The maximum purchase price consideration of \$4,355,600 was discounted to \$3,842,000, at August 11, 2021 and an accretion expense of \$82,973 was recognized in Net finance costs in the Consolidated Statement of Comprehensive Income for the three-month period ended March 31, 2022.

PyroGenesis Canada Inc. Notes to the Condensed Consolidated Interim Financial Statements

For the periods ended March 31, 2022 and 2021 (Unaudited)

5. Revenues

The following is a summary of the Company's revenues by product line:

	March 31,	March 31
	2022	2021
	\$	\$
Revenue from contracts with customers by product line:		
PUREVAP™	441,605	625,086
DROSRITE™	900,079	2,740,725
Development and support related to systems supplied to the U.S. Navy	745,260	2,586,021
Torch related sales	1,041,709	195,221
Biogas upgrading and pollution controls	990,045	_
Other sales and services	88,064	117,450
	4,206,762	6,264,503

The following is a summary of the Company's revenues by revenue recognition method:

	March 31,	March 31, 2021	
	2022		
	\$	\$	
Revenue from contracts with customers:			
Sales of goods under long-term contracts recognized over time	3,681,601	6,049,885	
Sales of goods at a point of time	525,161	214,618	
Other revenue:			
Sale of intellectual properties (i)	-	_	
	4,206,762	6,264,503	

See note 24 for sales by geographic area.

Transaction price allocated to remaining performance obligations

As at March 31, 2022, revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially satisfied) at the reporting date is \$41,189,745 (2021 - \$43,458,148). Revenue will be recognized as the Company satisfies its performance obligations under long-term contracts, which is expected to occur over the next 3 years.

6. Cash and cash equivalents

As at March 31, 2022, there are no restrictions on cash and cash equivalents. Cash and cash equivalents include the following components:

	March 31,	December 31,
	2022	2021
	\$	\$
Cash	3,612,624	3,568,561
Guaranteed investment certificates	3,000,000	8,633,952
Cash and cash equivalents	6,612,624	12,202,513

Guaranteed investment certificates are instruments issued by Canadian financial institutions and include \$3,000,000 bearing interest at a rate of 0.37%, These instruments are redeemable without penalty and mature between September 2022 and December 2022.

For the periods ended March 31, 2022 and 2021 (Unaudited)

7. Accounts receivable

Details of accounts receivable were as follows:

	March 31,	December 31,
	2022	2021
	\$	\$
1 – 30 days	1,158,260	2,260,428
31 – 60 days	91,980	44,838
61 – 90 days	74,077	6,855,822
Greater than 90 days	14,368,690	7,357,825
Total trade accounts receivable	15,693,007	16,518,913
Other receivables	286,022	270,536
Sales tax receivable	1,197,997	850,167
	17,177,027	17,639,616

As at March 31, 2022 the allowance for expected credit loss is \$520,000 (2021 - \$520,000), which was included through the business combination and has not changed throughout the three-month period.

8. Costs and profits in excess of billings on uncompleted contracts

As at March 31, 2022, the Company had seventeen contracts with total billings of \$17,716,248 which were less than total costs incurred and had recognized cumulative revenue of \$23,580,183 since those projects began. This compares with fourteen contracts with total billings of \$16,676,700 which were less than total costs incurred and had recognized cumulative revenue of \$21,599,410 as at December 31, 2021.

Changes in costs and profits in excess of billings on uncompleted contracts during the year are explained by \$104,689 (2021 - \$983,819) recognized at the beginning of the year being transferred to accounts receivable, and \$1,045,913.56 (2021 - \$4,832,968) resulting from changes in the measure of progress.

9. Investment tax credits

An amount recognized in 2022 included \$10,498 (2021 - \$202,472) of investment tax credits earned in the year, as well as \$Nil (2021 - \$706,000) of investment tax credits earned in prior years that no longer met the criteria for recognition in 2021. \$1,829 (2021 - \$148,695) of the investment tax credits recognized in the year was recorded against cost of sales and services, \$1,168 (2021 - (\$684,709)) against research and development expenses and \$7,500 (2021 - \$32,486) against selling general and administrative expenses.

PyroGenesis Canada Inc. Notes to the Condensed Consolidated Interim Financial Statements

For the periods ended March 31, 2022 and 2021 (Unaudited)

10. Strategic investments

	March 31,	December 31,
	2022	2021
	\$	\$
Beauce Gold Fields ("BGF") shares – level 1	112,837	123,095
HPQ Silicon Resources Inc. ("HPQ") shares - level 1	11,890,111	12,306,196
HPQ warrants – level 3	2,678,465	2,472,368
	14,681,413	14,901,659

The change in the strategic investments is summarized as follows:

	("BGF") sha	("BGF") shares – level 1 ("H) shares - level 1	HPQ	warrants - level 3
	Quantity	\$	Quantity	\$	Quantity	\$
Balance, December 31, 2020	1,025,794	123,095	14,990,200	16,489,220	25,844,600	23,379,435
Additions	-	-	8,268,000	8,070,109	-	-
Exercised	-	_	16,250,000	11,700,000	(16,250,000)	(9,181,250)
Disposed	-	_	(12,755,600)	(14,252,732)	-	-
Change in the fair value	-	_	-	(9,700,401)	-	(11,725,817)
Balance, December 31, 2021	1,025,794	123,095	26,752,600	12,306,196	9,594,600	2,472,368
Disposed	-	-	(3,887,000)	(1,397,001)	-	-
Change in the fair value	-	(10,258)	-	980,916	-	206,097
Balance, March 31, 2022	1,025,794	112,837	22,865,600	11,890,111	9,594,600	2,678,465

At March 31, 2022 and December 31, 2021, the fair value of the HPQ warrants was measured using the Black-Scholes option pricing model using the following assumptions:

	Ν	March 31, 2022			December 31, 2021			
Number of warrants	1,200,000	4,394,600	4,000,000	1,200,000	4,394,600	4,000,000		
Date of issuance	April 29, 2020	June 2, 2020	Sept. 3, 2020	April 29, 2020	June 2, 2020	Sept. 3, 2020		
Exercise price (\$)	0.10	0.10	0.61	0.10	0.10	0.61		
Assumptions under the Back Sholes model:								
Fair value of the shares (\$)	0.52	0.52	0.52	0.46	0.46	0.46		
Risk free interest rate (%)	2.22	2.22	2.22	1.22	1.22	1.22		
Expected volatility (%)	77.75	79.77	85.9	89.88	94.01	110.47		
Expected dividend yield	-	-	-	-	-	-		
Contractual remaining life (in months)	13	14	17	16	17	20		

As at March 31, 2022, a gain from initial recognition of the warrants of \$430,155 (\$510,573 at December 31, 2021) has been deferred off balance sheet until realized.

PyroGenesis Canada Inc. Notes to the Condensed Consolidated Interim Financial Statements

For the periods ended March 31, 2022 and 2021 (Unaudited)

11. Deposits

	March 31,	December 31,
	2022	2021
	\$	\$
Current portion:		
Suppliers	2,310,090	1,236,211
Security deposit on leased premises	92,241	92,241
Total current	2,402,331	1,328,452
Non-current portion:		
Suppliers	1,908	1,952
Security deposit on leased premises	234,390	246,804
Total non-current	236,297	248,756
Total Deposits	2,638,628	1,577,208

12. Accounts payable and accrued liabilities

	March 31,	December 31,
	2022	2021
	\$	\$
Accounts payable	6,060,701	5,457,259
Accrued liabilities	2,474,990	3,730,048
Sale commissions payable ¹	737,364	737,364
Accounts payable to the controlling shareholder and CEO	105,777	144,506
	9,378,832	10,069,177

Sale commissions payable relate to the costs to obtain long-term contracts with clients.

13. Billings in excess of costs and profits on uncompleted contracts

The amount to date of costs incurred and recognized profits less recognized losses for construction projects in progress amounted to \$23,658,662 (2021 - \$21,834,137).

Payments to date received were \$32,735,280 on contracts in progress (2021 - \$31,234,368).

Changes in billings in excess of costs and profits on uncompleted contracts during the year are explained by \$1,510,567 (2021 - \$6,268,910) recognized at the beginning of the year being recognized as revenue, and an increase of \$1,186,953 (2021 - \$9,076,169) resulting from cash received excluding amounts recognized as revenue.

For the periods ended March 31, 2022 and 2021

14. Term loans

	Economic			Canada	
	Development Agency	Other Term	Other Term	Emergency Business	
	of Canada Loan ¹	Loans ²	Loans ³	Account Loan ⁴	Total
	\$	\$	\$	\$	\$
Balance, December 31, 2021	87,985	24,700	28,220	50,000	190,905
Addition	155,735	-	_	-	155,735
Financing costs	(48,035)	-	-	-	(48,035)
Accretion	4,781	-	_	-	4,781
Payments	_	(3,186)	(4,980)	-	(8,166)
Balance, March 31, 2022	200,466	21,514	23,240	50,000	295,219
Less current portion	-	(13,313)	(19,920)	(50,000)	(83,233)
Balance, March 31, 2022	200,466	8,200	3,320	_	211,986

¹ Maturing in 2027, non-interest bearing, payable in 60 equal instalments from July 2023 to June 2027. In January 2022 the Company

received additional contributions of \$155,735 which was discounted using the effective interest method using a rate of 8%.

² Maturing October 23, 2023 bearing interest at a rate of 6.95% per annum, payable in monthly instalments of \$1,200 secured by

automobile (carrying amount of \$20,510 at March 31, 2022).

³ Maturing in May 2023, payable in monthly instalments of \$1,660, bearing interest at 7.45%.

⁴ Loan bearing no interest and no minimum repayment, if repaid by December 2023[.]

For the periods ended March 31, 2022 and 2021

15. Shareholders' equity

Common shares and warrants

Authorized:

The Company is authorized to issue an unlimited number of common shares without par value.

The following table sets out the activity in stock options:

	Number of options	Weighted average exercise price
		\$
Balance – December 31, 2020	9,040,000	1.57
Granted	2,970,000	4.55
Exercised ⁽¹⁾	(3,482,000)	0.32
Forfeited	(125,000)	4.41
Balance, December 31, 2021	8,403,000	3.10
Granted	450,000	3.36
Exercised	-	-
Forfeited	(10,000)	4.41
Balance, March 31, 2022	8,843,000	3.11

 $^{(1)}$ The weighted fair market value of the share price for options exercised in 2021 was \$5.48.

For the periods ended March 31, 2022 and 2021

15. Shareholders' equity (continued)

As at March 31, 2022, the outstanding options, as issued under the stock option plan to directors, officers, employees and consultants for the purchases of one common share per option, are as follows:

		Number of	Number of				Number of	
	Exercise	stock	stock				stock	
	price	options	options				options	
Expiry date	per option	vested (1)	March 31, 2022	Forfeitures	Exercised	Granted	mber 31, 2021	Dece
	\$							
November 3, 2022	0.58	2,400,000	2,400,000	-	-	-	2,400,000	November 3, 2017
July 3, 2023	0.51	300,000	300,000	-	-	-	300,000	July 3, 2018
October 29, 2023	0.52	40,000	40,000	-	-	-	40,000	October 29, 2018
September 29, 2024	0.51	100,000	100,000	-	-	-	100,000	September 29, 2019
January 2, 2025	0.45	100,000	100,000	-	-	-	100,000	January 2, 2020
July 16, 2025	4.41	1,343,000	2,233,000	(10,000)	-	-	2,243,000	July 16, 2020
October 26, 2025	4.00	125,000	250,000	-	-	-	250,000	October 26, 2020
April 6, 2026	8.47	320,000	550,000	-	-	-	550,000	April 6, 2021
June 1, 2026	6.59	50,000	200,000	-	-	-	200,000	June 1, 2021
June 14, 2026	6.70	25,000	100,000	-	-	-	100,000	June 14, 2021
October 14, 2026	5.04	10,000	100,000	-	-	-	100,000	October 14, 2021
December 17, 2026	3.13	1,920,000	1,920,000	_	-	-	1,920,000	December 17, 2021
December 30, 2026	3.61	100,000	100,000	_	-	-	100,000	December 30, 2021
January 3, 2027	3.36	450,000	450,000	_	-	450,000	_	January 3, 2022
	3.11	7,283,000	8,843,000	(10,000)	-	450,000	8,403,000	

⁽¹⁾ At March 31, 2022, the weighted average exercise price for options outstanding which are exercisable was \$2.64.

For the three-month period ended March 31, 2022, a stock-based compensation expense of \$1,669,630 (2021 - \$9,762,745) was recorded in Selling, general and administrative expenses in the Condensed Consolidated Statements of Comprehensive income (loss).

At March 31, 2022, an amount of \$2,027,944 (\$2,719,354 at December 31, 2021) remains to be amortized until January 2027 related to the grant of stock options.

For the periods ended March 31, 2022 and 2021

16. Supplemental disclosure of cash flow information

	March 31,	March 31,
	2022	2021
	\$	\$
Accounts receivable	462,589	(3,198,880)
Costs and profits in excess of billings on uncompleted contracts	(941,225)	508,729
Inventory	(385,571)	_
Investment tax credits receivable	45,885	(26,650)
Deposits	(1,061,420)	(1,382,100)
Contract assets	_	(2,811,894)
Prepaid expenses	(2,180,156)	_
Accounts payable and accrued liabilities	(640,057)	3,561,085
Billings in excess of costs and profits on uncompleted contracts	(323,610)	(2,658,774)
	(5,023,565)	(6,008,484)

17. Supplemental disclosure on comprehensive income statement

	March 31, 2022	March 31, 2021
	\$	\$
Inventories recognized in cost of sales	212,595	-
Amortization of intangible assets	218,759	6,780
Depreciation of property and equipment	142,990	76,317
Depreciation of ROU assets	166,224	101,794
Employee benefits	4,380,499	2,893,901
Share-based expenses	1,669,630	922,340
Awarded grants	39,434	59,179
	6,830,131	4,060,311

For the periods ended March 31, 2022 and 2021

18. Net finance costs

	March 31,	March 31,
	2022	2021
	\$	\$
Financial expenses		
Interest on term loans	851	3,508
Interest on lease liabilities	77,465	45,981
Interest accretion on balance due on business combination	82,973	_
Penalties and other interest expenses	23,975	3,598
	185,264	53,087
Financial income		
Accretion interest on royalty receivable	(1,364)	_
Net finance costs	183,900	53,087

19. Earnings (loss) per share

The following table provides a reconciliation between the number of basic and fully diluted shares outstanding for the three-month periods ended March 31:

	March 31,	March 31,	
	2022	2021	
	\$	\$	
Weighted daily average of Common shares	170,125,795	161,221,511	
Dilutive effect of stock options	-	6,103,135	
Dilutive effect of warrants	-	2,310,829	
Weighted average number of diluted shares	170,125,795	169,635,475	
Number of anti-dilutive stock options and warrants			
excluded from fully diluted earnings per share calculation	8,843,000	2,445,000	

20. Related party transactions

During the three months ended March 31, 2022, the Company concluded the following transactions with related parties:

In January 2020, the Company entered into a lease agreement for the rental of a property with a trust whose beneficiary is the controlling shareholder and CEO of the Company. At March 31, 2022 the carrying amount of the ROU asset and lease liabilities are \$1,051,774 and \$Nil (\$1,107,131 and \$Nil, respectively, at December 31, 2021)

Rent and property taxes were charged by a trust whose beneficiary is the controlling shareholder and CEO of the Company in the amount of \$69,054 and \$67,945 for the three-month periods ended March 31, 2022 and 2021, respectively.

For the periods ended March 31, 2022 and 2021

20. Related party transactions (continued)

A balance due to the controlling shareholder and CEO of the Company amounted to \$105,777 (\$144,506 at December 31, 2021) and is included in accounts payable and accrued liabilities.

The Key Management Personnel of the Company, in accordance with *IAS* 24, are the members of the Board of Directors and certain officers. Total compensation to key management, for the three-month periods consisted of the following:

	March 31,	March 31	
	2022	2021	
	\$	\$	
Salaries – key management	315,971	241,559	
Pension contributions	5,893	4,436	
Fees – Board of Directors	20,000	33,500	
Share-based compensation – officers	326,074	479,617	
Share-based compensation – Board of Directors	652,147	172,216	
Other benefits – key management	6,439	9,988	
Total compensation	1,326,524	941,316	

21. Financial instruments

As part of its operations, the Company carries a number of financial instruments. It is management's opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments except as otherwise disclosed. The Company's overall risk management program focuses on the unpredictability of the financial market and seeks to minimize potential adverse effects on the Company's financial performance. The Company does not use derivative financial instruments to hedge these risks.

Foreign currency risk

The Company enters into transactions denominated in US dollars for which the related revenues, expenses, accounts receivable and accounts payable and accrued liabilities balances are subject to exchange rate fluctuations.

As at March 31, 2022 and December 31, 2021 the Company's exposure to foreign exchange risk for amounts denominated in US dollars is as follows:

	March 31,	December 31,
	2022	2021
	\$	\$
Cash	795,163	1,714,670
Accounts receivable	14,605,695	14,465,011
Accounts payable and accrued liabilities	(2,518,815)	(1,023,999)
Total	12,882,043	15,155,682

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

Sensitivity analysis

At March 31, 2022, if the US Dollar changes by 10% against the Canadian dollar with all other variables held constant, the impact on pre-tax gain or loss and equity for the period ended March 31, 2022 would have been \$1,288,204 (December 31, 2021 - \$1,516,000).

For the periods ended March 31, 2022 and 2021

21. Financial instruments (continued)

Credit risk and credit concentration

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The maximum credit risk to which the Company is exposed as at March 31, 2022 represents the carrying amount of cash and cash equivalents, accounts receivable (except sales tax receivable), deposits and royalties receivable. Cash and cash equivalents, which only comprise guaranteed investment certificates redeemable on relatively short notice by the Company, are held with major reputable financial institutions. The Company manages its credit risk by performing credit assessments of its customers. The Company does not generally require collateral or other security from customers on accounts receivable. The Company believes that there is no unusual exposure associated with the collection of these receivables. During the three-month period ended March 31, 2022, 3 customers accounted for 49% of revenues from operations (3 customers accounted for 91% for the three-month period ended March 31, 2021).

	Three months ended March 31, 2022		Three months ended Ma	rch 31, 2022
		% of total		% of total
	Revenues	revenues	Revenues	revenues
	\$	%	\$	%
Customer 1	745,260	18	2,733,107	43
Customer 2	723,571	17	2,371,403	38
Customer 3	594,142	14	625,086	10
Total	2,062,973	49	5,729,596	91

Two customers accounted for 90% (one customer for 73% at December 31, 2021) of trade accounts receivable with amounts owing to the Company of \$14,582,568 (\$12,063,636 at December 31, 2021), representing the Company's major credit risk exposure. Credit concentration is determined based on customers representing 10% or more of total revenues and/or total accounts receivable.

The royalties receivables are due from a company in which the Company has a strategic investments. The Company does not have collateral or other security associated with the collection of this receivable.

Fair value of financial instruments

The fair value represents the amount that would be received for the sale of an asset or paid for the transfer of a liability in an orderly transaction between market participants at the measurement date. The fair value estimates are calculated at a specific date taking into consideration assumptions regarding the amounts, the timing of estimated future cash flows and discount rates. Accordingly, due to its approximate and subjective nature, the fair value must not be interpreted as being realizable in an immediate settlement of the financial instruments.

There are three levels of fair value that reflect the significance of inputs used in determining fair values of financial instruments:

Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 — inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 — inputs for the asset or liability that are not based on observable market data.

The fair values of cash and cash equivalents, trade accounts receivable, deposits, accounts payable and accrued liabilities and bank indebtedness approximate their carrying amounts due to their short-term maturities.

For the periods ended March 31, 2022 and 2021

21. Financial instruments (continued)

Investments in BGF and HPQ shares are valued at quoted market prices and are classified as Level 1.

Royalties receivable are discounted according to their corresponding agreements and are classified as Level 2.

Investments in HPQ warrants are valued using the Black-Scholes pricing model and are classified as Level 3.

The fair value of the term loans and the balance due on business combination as at March 31, 2022 is determined using the discounted future cash flows method and management's estimates for market interest rates for similar issuances. Given their recent issuance, their fair market values correspond to their carrying amount.

Interest rate risk

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. Changes in market interest rates may have an effect on the cash flows associated with some financial assets and liabilities, known as cash flow risk, and on the fair value of other financial assets or liabilities, known as price risk, and on the fair value of investments or liabilities, known as price risk. The Company is exposed to a risk of fair value on cash equivalents, and term loans as those financial instruments bear interest at fixed rates.

Price risk

Price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market price (other than those arising from foreign currency risk and interest risk), whether those changes are caused by factors specific to the individual financial instrument or its issuers or factors affecting all similar financial instruments traded in the market. The most significant exposure to the price risk for the Company arises from its investments in shares and warrants of public companies quoted on the TSXV Exchange. If equity prices had increased or decreased by 25% as at March 31, 2022, with all other variables held constant, the Company's investments would have increased or decreased respectively, by approximately \$4,037,000 (\$4,042,000 at December 31, 2021).

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivery of cash or another financial asset. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities.

The following table summarizes the contractual amounts payable and maturities of financial liabilities and other liabilities at March 31, 2022:

	Carrying value	Total contractual amount	Less than one year	2-3 years	4-5 years	Over 5 years
	\$	\$	\$	\$	\$	\$
Accounts payable and						
accrued liabilities	9,378,832	9,378,832	9,378,832	-	-	-
Term loans	295,219	383,237	86,150	117,330	125,117	54,640
Balance due on						
business combination	4,035,176	4,355,600	2,395,580	1,960,020	-	-
Lease liabilities	5,276,805	6,614,192	3,220,750	710,493	561,628	2,121,321
	18,986,032	20,731,861	15,081,312	2,787,843	686,745	2,175,961

For the periods ended March 31, 2022 and 2021

21. Financial instruments (Continued)

Liquidity risk (Continued)

The Company's Canadian subsidiary benefits from a line of credit of \$500,000, and the Italian subsidiary benefits from a 400,000 Euro (\$554,000) line of credit. At March 31, 2022, \$436,237 was drawn on the Canadian facility and 366,157 Euro (\$507,238) was drawn on the Italian facility.

22. Contingent liabilities

The Company is currently a party to various legal proceedings. If management believes that a loss arising from these proceedings is probable and can reasonably be estimated, that amount of the loss is recorded. As additional information becomes available, any potential liability related to these proceedings is assessed and the estimates are revised, if necessary. Based on currently available information, management believes that the ultimate outcome of these proceedings, individually and in aggregate, will not have a material adverse effect on the Company's financial position or overall trends in results of operations.

The Company had received a government grant in prior years of approximately \$800,000 to assist with the development of a new system of advanced waste treatment systems technology. The grant is potentially repayable at the rate of 3% of any consideration received as a result of the project, for which funding has been received, to a maximum of the actual grant received. This repayment provision will remain in effect until May 30, 2024. The Company abandoned the project in 2011 and accordingly, no amount is expected to be repaid.

23. Capital management

The Company's objectives in managing capital are:

- a) To ensure sufficient liquidity to support its current operations and execute its business plan; and
- b) To provide adequate return to the shareholders

The Company's primary objectives when managing capital is to ensure the Company continues as a going concern as well as to maintain optimal returns to shareholders and benefits for other stakeholders.

The Company currently funds these requirements from cash flows from operations and with financing arrangements with third parties and shareholders. The Company is not subject to any externally imposed capital requirements.

The Company monitors its working capital in order to meet its financial obligations. At March 31, 2022, the Company's working capital was \$12,346,374 (\$14,006,785 at December 31, 2021)

The management of capital includes shareholders' equity for a total amount of \$38,369,265 and term loans of \$295,219 (\$40,768,754 and \$190,905 respectively at December 31, 2021), as well as cash and cash equivalents amounting to \$6,612,624 (\$12,202,513 at December 31, 2021)

There were no significant changes in the Company's approach during the current three-month period and 2021 fiscal year, however, in order to maintain or adjust the capital structure, the Company may issue new shares, sell portions of its strategic investment and periodically purchase its own shares on the open market.

For the periods ended March 31, 2022 and 2021

24. Segment information

The Company operates in one segment, based on financial information that is available and evaluated by the Company's Board of Directors. The Company's head office is located in Montreal, Quebec. The operations of the Company are located in three geographic areas: Canada, Italy and India.

The following is a summary of the Company's revenue from external customers, by geography:

	March 31,	March 31,
	2022	2021
	\$	\$
Canada	1,367,792	799,433
United States	745,287	2,593,965
Europe	382,288	20,042
Mexico	176,508	_
Asia	315,831	_
Saudi Arabia	723,571	2,733,107
China	-	7,618
South America	122,471	110,338
India	373,015	_
	4,206,762	6,264,503

Revenue by product line and revenues recognized by revenue recognition method are presented in note 5.

25. Subsequent event

On April 20, 2022 the Company participated in an HPQ non-brokered private placement by acquiring 6,800,000 units at a price of \$0.53 per unit for a total investment of \$3,604,000. Each unit consists of one common share of HPQ and one common share purchase warrant. Each of these warrants entitles the Company to purchase one common share at a price of \$0.60 for a period of 24 months from the closing date of the private placement.